Katzenell Dimant /

KD represents Steadymed in its acquisition by United Therapeutics for up to $216 million


KD has represented Steadymed since its early phase as an incubator company, and throughout its listing in the NASDAQ, including private and public fund raises, handling commercial aspects of Steadymed’s activity and more.

For more information about the acquisition, see publications in themarker and globes.




read more in: